For the first time, this study shows in humans, dynamic inhibition of LSD1 in breast cancer CTC with associated reduction in expression of mesenchymal markers such as EGFR, FOXQ1, CSV and SNAI1 (6, 27). This evidence concerns the gene FOXQ1 and breast cancer.